On Tuesday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: BioCryst Pharmaceuticals, (NASDAQ:BCRX), Agilent Technologies (NYSE:A), Achillion Pharmaceuticals, (NASDAQ:ACHN), Comcast (NASDAQ:CMCSA)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) decreased -2.66%, and closed at $8.78. The company holds the market capitalization of $652.33M. For the last twelve months, the stock was able to keep return on equity at -74.10%, while return on assets at -39.30%, in response to its return on investment at -43.40%. Its 20-day moving average decreased -12.27%, below 50-day moving average of -15.55%, below 200-day moving average of -22.74% from the latest market price of $8.78. The mean recommendation of analysts for this stock is 2.20. (Where 1=Buy, 5=Sale).
BioCryst Pharmaceuticals, Inc. (BCRX) a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases
On March 18, 2015 Agilent Technologies Inc (NYSE:A) disclosed that a quarterly dividend of 10 cents per share of ordinary stock will be paid on April 22, 2015, to all shareholders of record as of the close of business on March 31, 2015. The timing and amounts of future dividends are subject to determination and approval by Agilent’s board.
Agilent Technologies Inc (NYSE:A) declined -2.63%, and closed at $41.09. The company has the market capitalization of $14.17 billion. The beta value of the stock is 1.55. On the other hand the stock’s volatility for the week is 1.71%, and for the month is 1.32%. The stock’s price to book ratio is $3.26, however price to sale ratio is $2.18. Analyst’s mean recommendation regarding this stock is 2.30. (Where 1=Buy, 5=Sale).
Agilent Technologies Inc (A) provides bio-analytical solutions and services to the life sciences, diagnostics and genomics, chemical analysis, communications, and electronics industries worldwide. The corporation’s Life Sciences and Diagnostics segment offers liquid chromatography systems, columns, and components; liquid chromatography mass spectrometry systems; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; nucleic acid solutions; nuclear magnetic resonance, magnetic resonance imaging, and X-ray diffraction systems; immunohistochemistry; in situ hybridization; hematoxylin and eosin staining; special staining, DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation and gene expression profiling; next generation sequencing target enrichment; and automated gel electrophoresis-based sample analysis systems.
Formerly On March 5, 2015 Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) unveiled financial results for the three and twelve months ended December 31, 2014.
For the three months ended December 31, 2014, the Corporation stated a net loss of $21.6 million, contrast to a net loss of $13.4 million in the three months ended December 31, 2013. For the full year ended December 31, 2014, the Corporation’s net loss was $69.0 million, or $0.70 per share, contrast to a net loss of $58.9 million for the year ended December 31, 2013, or $0.63 per share. Cash, cash equivalents, marketable securities, and interest and subscriptions receivable at December 31, 2014 were $159.2 million.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) fell -2.63%, and closed at $10.56. The stock has the beta value of 1.91, and its volatility for the week is 3.66%, while for the month it is 4.90%. The company has the market capitalization of $1.27 billion. The company holds the book value per share of 1.43, whereas cash per share is 1.30. Price to book ratio remained 7.38. Analysts mean recommendation for the stock is said to be 2.30 (where 1=Buy, 5=sale).
Achillion Pharmaceuticals, Inc. (ACHN) a biopharmaceutical corporation, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
On March 23, 2015 Comcast Corporation (NASDAQ:CMCSA) will host a symposium call with the financial community to talk about financial results for the first quarter on Monday, May 4, 2015 at 8:30 a.m. Eastern Time (ET). Comcast will issue a press release reporting its results earlier that morning.
Comcast Corporation (NASDAQ:CMCSA)’s shares picked down -2.62%, and closed at $57.57. The stock volatility for the week is 1.49%, while for the month remained 1.40%. The company holds consensus target price of $65.87.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 3.20 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 25.00% and Annual EPS growth for the past 5 years is considered as 20.50%.
The mean recommendation of analysts for this stock is 1.70. (Where 1=Buy, 5=Sale).
Comcast Corporation (CMCSA) works as a media and technology corporation worldwide. It operates through Cable Communications, Cable Networks, Broadcast Television, Filmed Entertainment, and Theme Parks segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
